Home › Psoriasis › NCT04119102

Duobrii in Combination With Biologics

Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Male or female adult ≥ 18 years of age;
2. Diagnosis of chronic plaque-type
3. Psoriasis affecting 2%-10% BSA
4. Patient is being treated with biologic therapy for a minimum of 24 weeks
5. Able and willing to give written informed consent prior to performance of any study-related procedures

Exclusion Criteria:

1. Psoriasis affecting ˂2% or \>10% BSA
2. Patient not receiving a biologic agent, or receiving biologic agent \<24weeks
3. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit.
4. Has previously used DUOBRII

About the study

12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks

What is being tested

• Duobrii (drug)

Sponsor: Psoriasis Treatment Center of Central New Jersey · Participants: 25 · Started: Oct 14, 2019

Contact the study team

• Jerry Bagel, MD · Phone: 6094434500
• Elise Nelson · Phone: 6094434500

Official record on ClinicalTrials.gov — NCT04119102

Locations in the U.S.

Conditions

• Psoriasis

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.